Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Technology Strategy Board of UK has granted funds worth £250,000 to Domainex for the development of a new drug to treat various types of cancers.
Subscribe to our email newsletter
The new drug will inhibit two protein kinase enzymes, TBK1 and IKKe, which will suppress the growth of certain cancer cell lines.
The project aims to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.
Domainex research director Trevor Perrior said the novel mode of action will allow the treatment of patients with drug-resistant triple-negative tumours.